Equities

Polynovo Ltd

Polynovo Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)2.58
  • Today's Change-0.03 / -1.15%
  • Shares traded723.86k
  • 1 Year change+63.29%
  • Beta1.8217
Data delayed at least 20 minutes, as of Jul 30 2024 07:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PolyNovo Limited is an Australia-based medical device company, which is focused on advanced wound care that designs, develops, and manufactures dermal regeneration solutions using its patented NovoSorb biodegradable polymer technology. Its solutions include NovoSorb Biodegradable Temporizing Matrix (BTM) and NovoSorb MTX. NovoSorb BTM is a synthetic, biodegradable and biocompatible device designed to facilitate the dermis to grow within a patented polyurethane matrix when lost through extensive surgery, trauma or burn. NovoSorb BTM is indicated for use in the management of wounds, including partial and full thickness wounds, pressure ulcers, venous and diabetic ulcers, chronic and vascular ulcers, surgical wounds, trauma wounds and draining wounds. Its development program covers breast sling, hernia, and orthopedic applications. NovoSorb MTX is available in a range of sizes to address acute and chronic dermal wounds and is comprised of a 2mm biodegradable foam with no sealing membrane.

  • Revenue in AUD (TTM)84.68m
  • Net income in AUD1.59m
  • Incorporated1998
  • Employees237.00
  • Location
    Polynovo Ltd2/320 Lorimer StreetMELBOURNE 3207AustraliaAUS
  • Phone+61 80095-8289
  • Fax+61 38681-4099
  • Websitehttps://polynovo.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vcanbio Cell & Gene Engineering Corp Ltd338.61m22.97m1.54bn2.21k66.881.98--4.540.23340.23343.447.880.30342.012.86728,818.101.971.132.791.6167.9767.766.513.841.526.930.02840.002.243.78-5.7812.43-7.11--
Pegavision Corp327.78m84.90m1.58bn589.0018.133.5312.404.8324.0724.0793.55123.710.59055.158.98--15.4714.5721.9720.1255.2551.6426.1921.751.39--0.10533.677.4116.737.3825.07-5.9446.64
Shanghai Runda Medical Technology Co Ltd1.90bn45.19m1.60bn3.32k34.071.75--0.83920.37190.371915.657.220.62194.661.562,727,524.002.554.787.0412.8626.0227.134.106.361.067.840.556812.43-12.848.93-34.580.85143.881.03
Paramount Bed Holdings Co Ltd1.04bn92.48m1.62bn4.13k16.471.1110.721.56161.05161.051,809.032,381.850.60394.574.5125,410,320.005.375.596.116.5947.6646.918.909.593.85--0.044536.657.085.7715.279.6416.645.39
Shandong Weigao Orthopaedic Devce Co Ltd261.15m11.16m1.65bn2.21k147.692.02--6.330.1330.1333.109.730.23690.66543.46561,846.201.0510.971.3413.6960.9077.334.4227.083.37--0.016117.90-30.551.17-79.36-19.11-4.31--
Riverstone Holdings Ltd303.48m80.55m1.66bn--20.602.8916.515.480.04780.04780.18010.34140.4786.416.69--12.6931.4213.4235.2335.7446.4326.5433.8111.356,502.920.000565.37-27.37-0.1362-29.9111.19-16.3438.99
Beijing Wandong Medical Technolgy Co Ltd271.33m40.25m1.75bn1.06k43.441.75--6.440.27190.27191.836.750.24442.334.281,218,206.003.705.304.126.2140.8145.2115.1416.4610.29--0.014435.8210.305.327.514.22-16.665.39
Angelalign Technology Inc310.71m11.26m1.76bn2.88k155.772.5062.405.660.34120.34129.4221.270.31945.3316.70551,242.601.055.761.297.5962.3864.333.3013.984.12--0.0188--16.2424.75-74.99-2.2020.54--
Polynovo Ltd84.68m1.59m1.80bn237.001,134.7826.09457.4121.270.00230.00230.12070.100.90841.017.28388,440.701.71-9.031.98-10.9294.3093.521.88-10.494.52-0.5820.1817--59.5361.65-312.95--47.35--
MicroPort Scientific Corp1.45bn-728.98m1.82bn8.23k--1.58--1.26-2.04-2.044.073.220.23991.095.32901,814.10-16.38-11.85-27.68-18.0455.9762.96-68.28-44.431.26-4.210.5477--13.077.27-9.42--19.44--
Kossan Rubber Industries Berhad542.43m22.73m1.99bn5.85k87.181.5633.773.660.02710.02710.64591.520.3924--6.54281,798.901.7123.441.8128.35--56.264.3726.5013.15--0.002542.09-32.12-5.76-91.51-41.80-22.665.92
Qingdao Haier Biomedical Co Ltd479.77m85.42m2.04bn2.64k23.892.23--4.261.281.287.1913.720.40694.938.41865,378.007.3911.499.4215.2249.3049.9818.1725.202.53--0.029526.53-20.3622.07-32.4128.9420.64--
Shanghai Microport EP MedTech Co Ltd77.02m4.03m2.08bn577.00515.585.85--27.010.04080.04080.77823.590.20131.189.01634,687.401.05--1.11--61.35--5.24--12.39--0.014--26.46--85.17------
Data as of Jul 30 2024. Currency figures normalised to Polynovo Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

11.47%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 04 Jul 202421.75m3.15%
Vanguard Investments Australia Ltd.as of 30 Jun 202412.25m1.78%
Allianz Global Investors Asia Pacific Ltd.as of 30 Apr 202410.59m1.54%
BlackRock Fund Advisorsas of 04 Jul 20248.75m1.27%
FIL Investment Management (Hong Kong) Ltd.as of 31 May 20247.12m1.03%
Norges Bank Investment Managementas of 31 Dec 20236.45m0.93%
Netwealth Investments Ltd.as of 07 Aug 20234.28m0.62%
BetaShares Capital Ltd.as of 28 Jun 20243.72m0.54%
BlackRock Investment Management (Australia) Ltd.as of 04 Jul 20242.14m0.31%
BlackRock Asset Management North Asia Ltd.as of 30 Apr 20242.13m0.31%
More ▼
Data from 31 Dec 2023 - 25 Jul 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.